Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65
- 1 December 2006
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 108 (12) , 3945-3947
Abstract
Recently, protocols using high-dose melphalan chemotherapy and autologous peripheral blood stem cell transplantation (HDM/SCT) have been developed for the treatment of patients with immunoglobulin light chain (AL) amyloidosis. Although peritransplantation mortality is greater than for other hematologic diseases, treatment leads to durable hematologic complete responses, improvements in organ function and quality of life, and extended survival in a substantial proportion of patients. To determine whether this treatment can be applied to older patients, we have analyzed HDM/SCT treatment outcomes for 65 patients (aged 65 years or older) with AL amyloidosis compared with outcomes for 280 younger patients. For patients over age 65 years who meet the same eligibility criteria as younger patients, toxicity, hematologic remission rate, and survival were not significantly different from those observed in younger patients, indicating that older patients should not be excluded a priori from consideration for HDM/SCT treatment.Keywords
This publication has 15 references indexed in Scilit:
- Outcome of autologous stem cell transplantation for AL amyloidosis in the UKBritish Journal of Haematology, 2006
- Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosisBone Marrow Transplantation, 2005
- Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosisBone Marrow Transplantation, 2005
- Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantationBlood, 2004
- Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control studyBlood, 2004
- High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year StudyAnnals of Internal Medicine, 2004
- Stem cell transplantation for the management of primary systemic amyloidosisThe American Journal of Medicine, 2002
- Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 yearsBritish Journal of Haematology, 2001
- The role of autologous transplantation in patients with multiple myeloma aged 65 years and overBone Marrow Transplantation, 2000
- Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myelomaBone Marrow Transplantation, 1998